GRIDAI TECHNOLOGIES CORP (GRDX) Stock Fundamental Analysis

NASDAQ:GRDX • US33749P5070

2.7 USD
-0.02 (-0.74%)
At close: Feb 20, 2026
3 USD
+0.3 (+11.11%)
After Hours: 2/13/2026, 8:13:59 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to GRDX. GRDX was compared to 521 industry peers in the Biotechnology industry. GRDX has a bad profitability rating. Also its financial health evaluation is rather negative. GRDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • GRDX had negative earnings in the past year.
  • In the past year GRDX has reported a negative cash flow from operations.
  • In the past 5 years GRDX always reported negative net income.
  • In the past 5 years GRDX always reported negative operating cash flow.
GRDX Yearly Net Income VS EBIT VS OCF VS FCFGRDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • With an excellent Return On Assets value of -11.81%, GRDX belongs to the best of the industry, outperforming 83.30% of the companies in the same industry.
  • The Return On Equity of GRDX (-18.98%) is better than 83.88% of its industry peers.
Industry RankSector Rank
ROA -11.81%
ROE -18.98%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRDX Yearly ROA, ROE, ROICGRDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GRDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRDX Yearly Profit, Operating, Gross MarginsGRDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2023 2024

3

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, GRDX has more shares outstanding
  • GRDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRDX Yearly Shares OutstandingGRDX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
GRDX Yearly Total Debt VS Total AssetsGRDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -1.63, we must say that GRDX is in the distress zone and has some risk of bankruptcy.
  • GRDX's Altman-Z score of -1.63 is in line compared to the rest of the industry. GRDX outperforms 52.98% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that GRDX is not too dependend on debt financing.
  • GRDX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. GRDX outperforms 46.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.63
ROIC/WACCN/A
WACCN/A
GRDX Yearly LT Debt VS Equity VS FCFGRDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 2.62 indicates that GRDX has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.62, GRDX is not doing good in the industry: 69.29% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.62 indicates that GRDX has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.62, GRDX is not doing good in the industry: 67.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 2.62
GRDX Yearly Current Assets VS Current LiabilitesGRDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.59% over the past year.
EPS 1Y (TTM)53.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -13.45% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRDX Yearly EPS VS EstimatesGRDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -100K -200K -300K

0

4. Valuation

4.1 Price/Earnings Ratio

  • GRDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRDX Price Earnings VS Forward Price EarningsGRDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRDX Per share dataGRDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • GRDX's earnings are expected to decrease with -13.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%

0

5. Dividend

5.1 Amount

  • GRDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

GRIDAI TECHNOLOGIES CORP

NASDAQ:GRDX (2/20/2026, 10:04:19 AM)

After market: 3 +0.3 (+11.11%)

2.7

-0.02 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-30
Inst Owners4.54%
Inst Owner ChangeN/A
Ins Owners2.89%
Ins Owner Change32.62%
Market Cap9.07M
Revenue(TTM)N/A
Net Income(TTM)-15.99M
Analysts43.33
Price TargetN/A
Short Float %1.6%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-10.09
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0
BVpS25.08
TBVpS10.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.81%
ROE -18.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 2.62
Altman-Z -1.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y80.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.53%
OCF growth 3YN/A
OCF growth 5YN/A

GRIDAI TECHNOLOGIES CORP / GRDX FAQ

What is the fundamental rating for GRDX stock?

ChartMill assigns a fundamental rating of 1 / 10 to GRDX.


What is the valuation status of GRIDAI TECHNOLOGIES CORP (GRDX) stock?

ChartMill assigns a valuation rating of 0 / 10 to GRIDAI TECHNOLOGIES CORP (GRDX). This can be considered as Overvalued.


How profitable is GRIDAI TECHNOLOGIES CORP (GRDX) stock?

GRIDAI TECHNOLOGIES CORP (GRDX) has a profitability rating of 2 / 10.